Library More-Data-More-Insights-More-Progress 
pharmaphorum
NOVEMBER 10, 2021
Tackling antimicrobial resistance (AMR) requires a one health approach that joins the dots between the human, animal, and environmental drivers, consequences, and data. Progress is complicated by AMR being notoriously difficult to measure, and, although most obvious in human health, resistance emerges in animal health and in the environment.
pharmaphorum
NOVEMBER 20, 2022
Parallel-running clinical development phases can mean rapid influxes of data alongside complex supply logistics and sample collection, which all need to be managed effectively to keep trials running smoothly. If an organisation is looking to expedite their progress in the vaccine space, a best practice approach will include targeted support.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
XTalks
NOVEMBER 7, 2022
These tumor-derived entities are used to derive genomic and proteomic data. Such information can reveal details about tumor staging, tumor progression, heterogeneity, gene mutations and clonal evolution. This will translate into a better quality of life and extended progression-free survival and overall survival for cancer patients.”.
The Pharma Data
DECEMBER 9, 2020
Our focus on partnering to accelerate patient access to innovative medicines underscores our commitment to advancing breakthroughs in biomedicine such as antibody drug conjugates, cell therapy, RNAi and more, Ed Zhang, company co-founder, chief operating and business officer, said in a statement. “We million in a second financing round.
Drug Discovery World
JANUARY 12, 2023
Scientists use complex gene editing and disease modeling systems to gain insights on the potential of CRISPR. . They also capture the tissue environment more closely than 2D cultures by growing 3D cell structures that mimic the organs they are modeling. Organoids avoid these challenges by modeling human tissue using human cells.
Drug Discovery World
JULY 22, 2022
But while psychedelic drug research has witnessed a relative roller-coaster ride of effort since the mid-20th century, more recent interest in the use of psychedelics for treating mental health and psychiatric disorders has spurred a raft of clinical trials 1. Psylo has imported and categorised all of the data into CDD.
The Pharma Data
SEPTEMBER 1, 2020
These data (Presentation #P0217) will be presented at the MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting. At months 24 and 36, 79% and 75% of participants, respectively, were relapse-free and 3- and 6-month confirmed disability progression was observed in 10.8% Studies Evaluating Novel Endpoints in Monitoring MS Disease Progression.
Expert insights. Personalized for you.
105 
Let's personalize your content